<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01449344</url>
  </required_header>
  <id_info>
    <org_study_id>MCL2005-01</org_study_id>
    <nct_id>NCT01449344</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL</brief_title>
  <acronym>(R-HAD)</acronym>
  <official_title>Efficacy and Safety of Rituximab, High-dose Ara-C and Dexamethasone (R-HAD) Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. M. Dreyling (co-chairman)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Klinikum der Universitaet Muenchen, Grosshadern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ClinAssess GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GELARC Service de Pharmacovigilance, Pierre Benite</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Mantle Cell Lymphoma Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of rituximab, high-dose
      ara-c and dexamethasone (r-had) alone or in combination with bortezomib in patients with
      relapsed or refractory mantle cell lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, randomized, multicenter, open-label phase III clinical trial to
      compare the efficacy and safety of Bortezomib in combination with Rituximab, high-dose Ara-C
      and dexamethasone (R-HAD) to R-HAD alone in patients with relapsed or refractory MCL after or
      not eligible for myeloablative treatment. The primary endpoint is time to treatment failure
      (TTF). Secondary endpoints are the complete response (CR) rate, the overall response (CR,PR)
      rate, the progression-free survival (PFS), the progression free survival of responders, the
      time to next lymphoma treatment, overall survival (OS), safety and tolerability of Rituximab,
      high-dose Ara-C and dexamethasone alone or in combination with Bortezomib. Study arms will be
      compared to each other to evaluate the impact of additional Bortezomib. Study arms will also
      be compared to historical controls.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 9, 2009</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline of diseased nodes and nodal masses.</measure>
    <time_frame>approx. 66 and 126 days after start of therapy</time_frame>
    <description>Average time frame is three weeks after the first two cycles of trial therapy and 4 to 6 weeks after the end of trial therapy.
Response is always evaluated in comparison to the status before start of trial therapy. The assessment will be done with CT of all known lymphoma manifestations. In case of isolated bone marrow involvement a bone marrow aspiration/ biopsy is mandatory. A minimum of 50 % decrease in SPD (sum of the products of the greatest diameters) of the six largest nodes or nodal masses are necessary, in order to be able to evaluate it as partly remission.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>R-HAD + Bortezomib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>R-HAD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab 375mg/m² IV , day 1</description>
    <arm_group_label>R-HAD + Bortezomib</arm_group_label>
    <arm_group_label>R-HAD</arm_group_label>
    <other_name>Rituximab:Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose Ara-C</intervention_name>
    <description>Ara-C 2000 mg/m² (patients &gt;65 years or s/p myeloablative treatment: 1000 mg/m²) IV, d 2 and 3</description>
    <arm_group_label>R-HAD + Bortezomib</arm_group_label>
    <arm_group_label>R-HAD</arm_group_label>
    <other_name>Ara-C: Cytarabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 40 mg PO, day 1-4</description>
    <arm_group_label>R-HAD + Bortezomib</arm_group_label>
    <arm_group_label>R-HAD</arm_group_label>
    <other_name>Dexamethasone: none</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Bortezomib 1.5 mg/m² IV, day 1 and 4</description>
    <arm_group_label>R-HAD + Bortezomib</arm_group_label>
    <other_name>Bortezomib: Velcade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed pathological diagnosis of MCL according to WHO classification.

          -  Relapse or progression following 1 to 3 prior lines of anti-neoplastic standard
             therapy. Therapy in remission after initial induction like intensified chemotherapy
             for stem cell separation followed by myeloablative therapy or any kind of maintenance
             therapy is classified as one line of therapy with the induction therapy..

          -  If Rituximab was part of prior treatment, documented time to progression must be at
             least 12 weeks after this particular regimen.

          -  If high-dose Ara-C was part of prior treatment, documented time to progression must be
             at least 6 months after this particular regimen.

          -  Patients relapsed after autologous stem cell transplantation or not appropriate for
             myeloablative treatment.

          -  At least 1 measurable or assessable site of disease; in case of bone marrow
             infiltration only, bone marrow aspiration/ biopsy is mandatory for all staging
             evaluations.

          -  age &gt; 18 years

          -  ECOG/WHO Performance Score 0-2 unless lymphoma related.

          -  The following laboratory values at screening, unless lymphoma related:

          -  Absolute neutrophil count (ANC) &gt; = 1500 cells/microlitre

          -  Platelets &gt; = 100,000 cells/microlitre

          -  Transaminases (AST and ALT) &lt;=3 x upper limit of normal (ULN)

          -  Total bilirubin &lt;=2 x ULN

          -  Creatinine &lt;=2 mg/dL or calculated creatinine clearance &gt;=50 mL/min

          -  Toxic effects of previous therapy or surgery resolved to NCI CTC grade 2 or better.

          -  Premenopausal fertile females must agree to use a highly effective method of birth
             control for the duration of the therapy. A highly effective method of birth control is
             defined as those which result in a low failure rate (i.e. less than 1% per year) when
             used consistently and correctly such as implants, injectables, combined oral
             contraceptives, some IUDs, sexual abstinence or vasectomised partner.

          -  Men must agree not to father a child for the duration of therapy and must agree to
             advice a female partner to use a highly effective method of birth control.

          -  Written informed consent before performance of any study-related procedure.

        Exclusion Criteria:

          -  Previous treatment with Bortezomib

          -  Treatment within another clinical trial within 30 days before trial entry or planned
             during this trial

          -  Anti-neoplastic (including radiation and antibody treatment) or experimental therapy
             within 4 weeks before planed Day 1 of Cycle 1 (Nitrosoureas within 6 weeks ) or
             radioimmunoconjugates or toxin immunoconjugates such as Ibritumomab tiuxetan
             (Zevalin™) or Tositumomab (Bexxar®) within 12 weeks before planed Day 1 of Cycle 1

          -  Known hypersensitivity to Rituximab, boron or mannitol.

          -  Active malignancy other than MCL within 5 years before Day 1 of Cycle 1, with the
             exception of complete resection of basal cell carcinoma, squamous cell carcinoma of
             the skin, or in situ malignancy.

          -  Active systemic infection requiring treatment.

          -  HIV, hepatitis B or C

          -  Patient has &gt;= grade 2 peripheral sensory neuropathy or neuropathic pain defined by
             the NCI Common Terminology Criteria for Adverse Events (CTCAE).

          -  Symptomatic degenerative or toxic encephalopathy

          -  Serious medical condition (such as severe hepatic impairment, pericardial disease,
             acute diffuse infiltrative pulmonary disease, systemic infections etc) or psychiatric
             illness likely to interfere with participation in this clinical study

          -  Female subject is pregnant or breast-feeding (pregnancy testing is mandatory for
             premenopausal women).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Dreyling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum der Universität München, Grosshadern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH Victor Dupouy, Service hématologie</name>
      <address>
        <city>Argenteuil Cedex</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la côte Basque, Service hématologie</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Blois, Service hématologie</name>
      <address>
        <city>Blois</city>
        <zip>41016</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie, Service Hématologie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Sud Francilien de Corbeil, Service hématologie</name>
      <address>
        <city>Corbeil Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor, Service hématologie</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Albert Michallon, Service hématologie</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Mulhouse, Service hématologie</name>
      <address>
        <city>Le Mans</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo, Service hématologie</name>
      <address>
        <city>Le Mans</city>
        <zip>72015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH du Mans, Service hématologie</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice, Service hématologie</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Necker, Service d'hématologie - adulte</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut Lévêque, Service hématologie</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud, Service hématologie</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Bernard, Service hématologie</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH René Dubos, Service hématologie</name>
      <address>
        <city>Pontoise</city>
        <zip>95301</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Robert Debré, Service hématologie</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bretonneau, Service hématologie, Bâtiment H. Kaplan</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brabois, Service hématologie</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Bretagne Atlantique, Service Hématologie</name>
      <address>
        <city>Vannes</city>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave ROUSSY</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreisklinik Altötting-Burghausen, Sektion Hämatologie/Onkologie und Palliativmedizin</name>
      <address>
        <city>Altötting</city>
        <zip>84503</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum St. Marien, Med. Klinik II</name>
      <address>
        <city>Amberg</city>
        <zip>92224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukölln, Medizinische Klinik I - Hämatologie und Onkologie</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knappschaftskrankenhaus, Onkologische Ambulanz</name>
      <address>
        <city>Bottrop</city>
        <zip>46242</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Hämatologie/Onkologie,</name>
      <address>
        <city>Burgwedel</city>
        <zip>30938</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marien Hospital Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40479</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Essen, Klinik für Hämatologie</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W. Goethe-Universtität Frankfurt, Medizinische Klinik II, Hämatologie/Onkologie</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ernst-Moritz-Arndt-Universität, Hämatologie/Onkologie</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kath. Krankenhaus Hagen gem. GmbH St.-Marien-Hospital</name>
      <address>
        <city>Hagen</city>
        <zip>58095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg, Abteilung Hämatologie</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.-Marien-Hopsital Gem. GmbH</name>
      <address>
        <city>Hamm</city>
        <zip>59071</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik des Saarlandes</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westpfalz-Klinikum GmbH, I. Medizinische Klinik</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>67653</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKSH im Städt. Krankenhaus Kiel, II. Med. Klinik und Poliklinik im SSK</name>
      <address>
        <city>Kiel</city>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität zu Köln, Klinik I f. Innere Medizin</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Vehling-Kaiser</name>
      <address>
        <city>Landshut</city>
        <zip>84028</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Magdeburg gemeinnützige GmbH, Klinik f. Hämatologie/Onkologie</name>
      <address>
        <city>Magdeburg</city>
        <zip>39130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum d. Phillips-Universität, Klinik für Innere Medizin Hämatol./Onkologie/Immunologie</name>
      <address>
        <city>Marburg</city>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Schwäbisch Gmünd, Zentrum Innere Medizin</name>
      <address>
        <city>Mutlangen</city>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Maria Hilf GmbH (Krankenhaus St. Franziskus)</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU München - Klinikum Großhadern Medizinische Klinik III</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nord Nürnberg, 5. Med. Klinik, Onkologie/Hämatologie</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schlossberg Klinik, Oberstaufen Internistische Onkologie</name>
      <address>
        <city>Oberstaufen</city>
        <zip>87534</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonie Klinikum Jung Stilling Krankenhaus</name>
      <address>
        <city>Siegen</city>
        <zip>57074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonieklinikum Stuttgart, Medizinische Klinik II</name>
      <address>
        <city>Stuttgart</city>
        <zip>70176</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus, Hämatologie/Onkologie</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mutterhaus der Borromäerinnen, Medizinische Abteilung</name>
      <address>
        <city>Trier</city>
        <zip>54219</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder, 1. Medizinische Abteilung</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Innere Medizin III</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harz-Klinikum Wernigerode-Blankenburg GmbH, Innere Medizin, Hämato-Onkologie und Palliativmedizin</name>
      <address>
        <city>Wernigerode</city>
        <zip>38855</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ammerland-Klinik GmbH, Klinik für innere Medizin</name>
      <address>
        <city>Westerstede</city>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heinrich-Braun-Krankenhaus, Klinik für Innere Medizin III</name>
      <address>
        <city>Zwickau</city>
        <zip>08060</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2011</study_first_submitted>
  <study_first_submitted_qc>October 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2011</study_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>European Mantle Cell Lymphoma Network</investigator_affiliation>
    <investigator_full_name>Prof. Dr. M. Dreyling (co-chairman)</investigator_full_name>
    <investigator_title>Coordinating investigator, Germany</investigator_title>
  </responsible_party>
  <keyword>relapsed</keyword>
  <keyword>refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

